Immutep announced that it has completed patient enrollment of the Phase 2b Active Immunotherapy
PAClitaxel, or AIPAC, clinical trial in HER2-negative/ hormone receptor positive metastatic breast cancer, or MBC.
Phase two of the clinical trial is exploring the tolerability and efficacy of the combination regimen of Transgene's TG4010, an investigational active immunotherapy
against MUC1 tumour-associated antigen, with Bristol-Myers Squibb's immune checkpoint inhibitor, Opdivo[R] (nivolumab), which acts by overcoming immune suppression, and standard platinum doublet chemotherapy.
This Phase 2 clinical trial is exploring the tolerability and efficacy of the combination regimen of Transgene's TG4010, an investigational active immunotherapy
against MUC1 tumor-associated antigen, with Bristol-Myers Squibb's immune checkpoint inhibitor, Opdivo (nivolumab), which acts by overcoming immune suppression, and standard platinum doublet chemotherapy.
LaCasse et al., "Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy
against BCR-ABL- tumors," Journal of Immunology, vol.
There are several active trials looking at combining therapies aimed at reducing toxicity with active immunotherapy
. In addition, the financial impact of this therapy can be large, and efforts are needed to develop less expensive therapies and treatment algorithms that help control cost.
This technology is based on active immunotherapy
to generate an immune response through the administration of an immunogenic complex involving the target cytokine to a carrier protein.
Although the active immunotherapy
has demonstrated some benefits for AD patients and there are high expectations of the ongoing clinical trials, the safety and the difficulty to treat adverse effects still raises concern and constitute the main drawback of this therapeutic approach.
Created in 1993, Neovacs is a biotechnology company focused on an active immunotherapy
technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases.
'Polycap (for prevention and treatment of cardiovascular diseases), Risorine (for treatment of tuberculosis) and Mycidac-C, the world's first active immunotherapy
for lung cancer, are three innovative drugs that we have developed.'[euro]oCi
This is a first in the class active immunotherapy
as well as drug targeting Desmocollin-3.
They describe strategies of passive and active immunotherapy
, improving immunotherapeutic responses using combinations of agents for immunochemotherapy, and targeting strategies to defeat immune suppression.